Introduction: Low-dose computed tomography, the currently used tool for lung cancer screening, is characterized by a high rate of false-positive results. Accumulating evidence has shown that cancer cell metabolism differs from that of normal cells. Therefore, this study aims to evaluate whether the metabolic phenotype of blood plasma allows detection of lung cancer.
Methods: The proton nuclear magnetic resonance spectrum of plasma is divided into 110 integration regions, representing the metabolic phenotype. These integration regions reflect the relative metabolite concentrations and were used to train a classification model in discriminating between 233 patients with lung cancer and 226 controls. The validity of the model was examined by classifying an independent cohort of 98 patients with lung cancer and 89 controls.
Results:
The model makes it possible to correctly classify 78% of patients with lung cancer and 92% of controls, with an area under the curve of 0.88. Important moreover is the fact that the model is convincing, which is demonstrated by validation in the independent cohort with a sensitivity of 71%, a specificity of 81%, and an area under the curve of 0.84. Patients with lung cancer have increased glucose and decreased lactate and phospholipid levels. The limited number of patients in the subgroups and their heterogeneous nature do not (yet) enable differentiation between histological subtypes and tumor stages.
Conclusions: Metabolic phenotyping of plasma allows detection of lung cancer, even in an early stage. Increased glucose and decreased lactate levels are pointing to an increased gluconeogenesis and are in accordance with recently published findings. Furthermore, decreased phospholipid levels confirm the enhanced membrane synthesis.
Introduction
Lung cancer is the leading cause of cancer death worldwide, with a 5-year survival rate of around 15%. 1, 2 A promising screening tool is low-dose computed *Corresponding author.
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Trial Registration: LC-NMR Study Biomarkers to Detect Lung Cancer. NCT02024113. tomography (LDCT), which has been shown to reduce lung cancer mortality by 20% as compared with chest radiography screening. 3 However, LDCT screening has some disadvantages, such as the high cost associated with screening all patients at risk according to current risk models, radiation exposure, and the low positive predictive value (PPV). 4 Because of these limitations, other detection platforms are being evaluated, all with their advantages and shortcomings. 5 Over the past decade, accumulating evidence has shown that cancer cell metabolism differs from that of normal cells. [6] [7] [8] More specifically, it is reprogrammed to promote cell proliferation and survival and is driven by aberrant signaling pathways induced by the activation of oncogenes/inactivation of tumor suppressor genes. 9 One of the main adaptations of cancer cells is that, even in the presence of normal oxygen levels, they rely on anaerobic energy production through glycolysis, a hallmark known as the Warburg effect. 10 As metabolites are the end products of cellular processes, changes in their concentration reflect alterations in the metabolic phenotype.
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Proton nuclear magnetic resonance ( 1 H-NMR)-based metabolomics allows a fast, noninvasive identification and quantification of complex mixtures of metabolites, as in plasma. [12] [13] [14] This study aims to (1) investigate whether the plasma metabolic phenotype allows discrimination between patients with lung cancer and controls, (2) evaluate the predictive accuracy of the trained classification model in an independent cohort, addition to being of help in understanding the changed metabolism, and (3) examine whether the metabolic phenotype allows discrimination between histological subtypes and tumor stages.
Materials and Methods

Subjects
Patients with lung cancer (n ¼ 357) were included in the Limburg Positron Emission Tomography Center (n ¼ 273) (Hasselt, Belgium) and at the Department of Respiratory Medicine of University Hospitals Leuven (n ¼ 84) (Leuven, Belgium) from March 2011 to June 2014. The diagnosis was confirmed by a pathological biopsy or by a clinician specialized in interpreting radiological and clinical lung cancer data. Clinical staging was performed according to the seventh edition of the tumor, node, and metastasis classification. 15 The controls (n ¼ 347) were patients with noncancer diseases who were included at Ziekenhuis Oost-Limburg (Genk, Belgium) between March 2012 and June 2014. The absence of malignant disease was confirmed on the basis of the hospital medical files. A double-check of the medical file was accomplished at the time of the statistical analysis for controls who were misclassified. None had malignant disease at the moment of statistical analysis. For both groups, blood sampling and sample preparation was performed according to a fixed protocol and by trained staff.
The exclusion criteria were as follows: (1) not fasted for at least 6 hours, (2) fasting blood glucose concentration of 200 mg/dL or higher, (3) medication intake on the morning of blood sampling, and (4) treatment or history of cancer in the past 5 years. The study was conducted in accordance with the ethical rules of the Helsinki Declaration and Good Clinical Practice and was approved by the involved ethical committees. Study participants provided informed consent.
Both groups were subdivided into a training cohort and a validation cohort (Fig. 1) . More specifically, 250 of the 357 patients with lung cancer and 250 of the 347 controls were randomly assigned to the training cohort, leaving a validation cohort of 107 patients with lung cancer and 97 controls. Forty-one statistical outliers in the training cohort (17 patients with lung cancer and 24 controls) and 17 in the validation cohort (9 patients with lung cancer and 8 controls) were excluded. According to their medical files, they showed abnormal concentrations of glucose, lipids, or ketone bodies. Individuals with high glucose levels were determined to have diabetes or an increased fasting glucose, whereas those with high lipid levels suffered from obesity or hyperlipidemia or were taking cholesterol-lowering medication. Most of the individuals with high levels of ketone bodies levels had a low body mass index.
Blood Sampling, Sample Preparation, and NMR Analysis
The protocols used have been described in detail. 16 
Statistical Analysis
Multivariate statistical analysis was performed using SIMCA-Pþ (Version 14, Umetrics, Malmö, Sweden). After mean centering and Pareto scaling of the variables, unsupervised principal component analysis (PCA) was performed to identify outliers by a Hotelling's T2 range test and a distance to model plot. After outliers had been removed, orthogonal partial least squares discriminant analysis (OPLS-DA) was used to train a classification model. The validity of the model was confirmed by (1) permutation testing; (2) classification of an independent cohort with a classification cutoff value of 0.5; (3) receiver operating characteristic curve explorer and tester; and (4) last but not least, comparison with the outcome of an independent model constructed by partial least squares discriminant analysis (PLS-DA) (R Version 3.1.2 [R Foundation for Statistical Computing, Vienna, Austria]). An S-plot was used to identify the most discriminating variables and their variable importance for the projection (VIP) values. Variables with a VIP value exceeding 0.5 were used to describe the disturbed biochemical pathways. Additionally, a Student's t test corrected for multiple testing by the BenjaminiHochberg method was applied.
Results
Multivariate OPLS-DA statistics were used to train a classification model (classifier) in discriminating between patients with lung cancer and controls on the basis of data input from their metabolic phenotype. The resulting model was validated in an independent cohort. Table 1 shows the characteristics of the training and validation cohorts. Before the OPLS-DA was started, however, PCA was conducted to look for possible confounders. Supplementary Figure 1 in the Supplementary Digital Content shows PCA score plots stained for disease (A), sex (B), smoking habits, (C) and chronic obstructive pulmonary disease (COPD) (D), demonstrating that smoking habits and sex are not confounders. Regarding COPD, the PCA results cannot be interpreted straightforwardly, but OPLS-DA confirmed that it is no confounder either (see later).
Applying OPLS-DA on the training set resulted in a model that allowed correct classification of 78% of the 233 patients with lung cancer and 92% of the 226 controls ( Figs. 2A and B) . Also, if the statistical outliers were not excluded, the OPLS-DA classification model stayed intact, allowing correct classification of 75% of 250 patients with lung cancer and 90% of 250 controls ( Supplementary Fig. 2 in the Supplementary Digital Content 2). An independent permutation test confirmed no overfitting ( Supplementary Fig. 3 in the Supplementary Digital Content). The predictive accuracy of the model was assessed by applying it to the independent cohort of 98 patients with lung cancer and 89 controls (Figs. 2B and C), resulting in a sensitivity of 71% and a specificity of 81%. The sensitivity, specificity, area under the curve (AUC), PPV, and negative predictive value of this model as well as of all other models are shown in Table 2 . To further confirm, the data set was analyzed independently (by the biostatistics research group) using PLS-DA. The resulting classifier permitted correct classification of 82% of the patients with lung cancer and 89% of the controls. Regarding the independent validation, the classifier was able to discriminate between the patients with lung cancer and controls with a sensitivity of 75% and a specificity of 82%. To exclude COPD as a confounder, an OPLS-DA model was trained in discriminating between subjects with (n ¼ 158) and without (n ¼ 301) COPD ( Supplementary Fig. 4 in the Supplementary Digital Content). The extremely poor predictive accuracy of the resulting model (Q2 ¼ 0.08) confirms that COPD is no confounder.
Regarding the differentiating metabolites, only those with a VIP value exceeding 0.5 (i.e. the 45 most differentiating) were selected ( Supplementary Fig. 5 in the Supplementary Digital Content). Supplementary Tables 6  and 7 in the Supplemental Digital Content show the variables (and contributing metabolites) that are increased/ decreased for patients with lung cancer together with their univariate p value and fold change. The metabolites whose concentration was increased were glucose, N-acetylated glycoproteins, b-hydroxybutyrate, leucine, lysine, tyrosine, threonine, glutamine, valine, and aspartate, whereas the metabolites whose concentration was decreased included alanine, lactate, sphingomyelin and phosphatidylcholine (and other cholinated phospholipids), citrate, and other phospholipids. It is noteworthy that sphingomyelin and phosphatidylcholine can be discriminated from other phospholipids on the basis of the strong NMR signal of the three methyl groups of their choline head group.
In the next step, whether histological subtypes and tumor stages can be discriminated on the basis of metabolic phenotype was evaluated. PCA was not able to cluster the histological subtypes, and the same held true for OPLS-DA ( Supplementary Fig. 8 in the Supplementary Digital Content). Because adenocarcinomas (n ¼ 91) and squamous carcinomas (n ¼ 66) are the most common histological subtypes (Table 1) , an OPLS-DA model was trained in discriminating between them. The resulting model classified 81% of the adenocarcinomas correctly but only 38% of the squamous carcinomas (Fig. 3) . Moreover, the predictive ability of the model was extremely poor (Q2 ¼ 0.04). Concerning tumor stage, no significant clustering was obtained by PCA or by OPLS-DA ( Supplementary Fig. 9 in the Supplementary Digital Content). In an attempt to further discriminate between patients with early-stage disease (stage I, n ¼ 76) and patients with metastatic disease (stage IV, n ¼ 63), a model was trained that correctly classified 79% of the patients with early-stage disease and 52% of the patients with metastatic disease (Fig. 4A ), but the predictive ability of this model was very low (Q2 ¼ 0.06). On the other hand, an OPLS-DA model was able to discriminate between patients with early-stage disease (stage I, n ¼ 76) and a randomly selected equally populated group of controls (n ¼ 76) with a sensitivity of 74% and a specificity of 78% (Fig. 4B) . Most of the discriminating variables of this model were also found for the full model.
Discussion
This study demonstrates that (1) the model allows correct classification of 78% of patients with lung cancer and 92% of controls with an AUC of 0.88; (2) the model discriminates between patients with lung cancer and controls of the independent cohort with a sensitivity of 71%, a specificity of 81%, and an AUC of 0.84; and (3) the limited number of patients in the subgroups and their heterogeneous nature regarding histological subtype and tumor stage do not (yet) allow discrimination between histological subtypes and tumor stages, but it appears that stage I patients can be reasonably well differentiated from controls. AUC, area under the curve; C, controls; LC, patients with lung cancer; LV, latent variable; NPV, negative predictive value; O, number of orthogonal components; OPLS-DA, orthogonal partial least squares discriminant analysis; P, number of predictive components; PLS-DA, partial least squares discriminant analysis; PPV, positive predictive value; R2X(Cum), total explained variation in X; R2Y(Cum), total explained variation in Y; Sens, sensitivity; Spec, specificity; Q2(Cum), predicted variation.
The metabolic phenotype, which is represented by the relative abundance of plasma metabolites, has to be seen as a single biomarker that cannot be defined on the basis of a cutoff value. It has been demonstrated that the combination of a series of subtle metabolic alterations (metabolites whose plasma concentration is increased/ decreased in patients with lung cancer compared with in controls) detected by 1 H-NMR spectroscopy and presented by OPLS-DA, enables diagnosis of lung cancer.
Recently, many studies have explored metabolism in patients with lung cancer, but mostly by mass spectrometry (MS) techniques rather than by 1 H-NMR spectroscopy. [17] [18] [19] Although MS is without doubt more sensitive, 1 H-NMR spectroscopy requires no invasive extraction procedures, and thus minimal sample preparation. 13 Both techniques are therefore complementary and of importance in the field of metabolomics. Furthermore, most published NMR studies have focused on the metabolic composition of the lung cancer tissue notwithstanding the fact that metabolic phenotyping of blood plasma has the advantage of assessing more directly the complex interaction between tumor and host. 20, 21 Moreover, blood samples can be obtained noninvasively and with minimal risk for the patient. 22 According to a review by Duarte et al., 23 only Rocha et al. 24 investigated lung cancer-induced metabolic alterations in plasma by 1 H-NMR spectroscopy, demonstrating a discrimination between 85 patients with lung cancer and 78 controls with a sensitivity and specificity of around 90%, but unfortunately without validation in an independent cohort.
H-NMR Metabolic Phenotyping of Plasma as a Complementary Tool to Identify High-Risk Individuals
Currently, LDCT is the most studied tool to screen for lung cancer. The NELSON trial demonstrates that LDCT screening has a sensitivity of 85% and a specificity of 99% in comparison with no screening. 25 However, a major limitation of LDCT is the low PPV, which ranged from 4% in the National Lung Screening Trial to 40% in the NELSON trial. This means that more than half of the study participants were referred for further investigations, which are not without cost and risk, on the basis of false-positive results. 3, 25 Strengthening of current risk models by incorporating metabolic phenotype information might be the way to better identify patients eligible for LDCT screening. In this respect, 1 H-NMR-based metabolomics seems to be reasonably able to discriminate between patients with early-stage disease and a randomly selected equally populated group of controls. This indicates that metabolic alterations present in the initial phase of cancer development can already be detected by 1 H-NMR-based metabolomics. Although these results look promising, they need to be confirmed by increasing the number of patients with early-stage disease in the study.
Although it was not the major aim of this study, we also looked at the altered lung cancer cell metabolism through the plasma metabolites that contribute the most to group differentiation. The presented findings demonstrate that phospholipids are decreased in the plasma of patients with lung cancer, which is in agreement with an enhanced membrane synthesis in cancer cells. [26] [27] [28] Furthermore, this study revealed that metabolism in patients with lung cancer is characterized by increased glucose and decreased lactate levels. These findings are in line with those of Chen et al., 18 who examined the serum metabolome of patients with lung cancer by means of MS and pointed to an increased gluconeogenesis in lung cancer cells. Also, a recent study by Leithner et al., 29 in which lung cancer cells were incubated with 13 C 3 -lactate to follow the conversion of metabolites along the gluconeogenic pathway, is in accordance with this conclusion. More specifically, they have shown that lactate serves as a gluconeogenic precursor and that phosphoenolpyruvate carboxykinase, the key gluconeogenic enzyme that converts oxaloacetate to phosphoenolpyruvate, is active in lung cancer cells. These findings indicate that lung cancer cells utilize at least some steps of the gluconeogenic pathway to adapt to low-glucose conditions as a result of insufficient blood flow. 6, 29 In conclusion, this paper validates 1 H-NMR metabolic phenotyping of blood plasma as a complementary tool to discriminate between patients with lung cancer and controls. Our findings indicate that metabolic alterations can already be detected in an early stage. It should be noted, however, that our intent is not to use the metabolome as a separate screening tool but to complement current risk models with additional parameters to better select highrisk individuals eligible for LDCT screening. Consequently, it might be anticipated that the PPV of LDCT screening will increase, thereby improving its cost-effectiveness. Because of the limited subgroup numbers and the heterogeneous nature of the subgroups, it is not yet possible to decide whether metabolic phenotyping can further discriminate between histological subtypes or tumor stages.
